[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]

Anadolu Kardiyol Derg. 2007 Mar;7(1):54-8.
[Article in Turkish]

Abstract

Nonvalvular atrial fibrillation is the most common cardiac arrhythmia associated with a substantial risk of thromboembolism and stroke. Despite numerous disadvantages that limit its efficacy and safety, warfarin is widely used in the prevention and treatment of thromboembolism related with atrial fibrillation. Ximelagatran, an oral direct thrombin inhibitor has the potential to be an alternative choice in the prevention and therapy of thromboembolism related with atrial fibrillation. Studies compared ximelagatran with warfarin in nonvalvular atrial fibrillation at risk for stroke showed that fixed dose oral ximelagatran is effective as adjusted dose warfarin in stroke prevention. Ximelagatran has numerous advantages over warfarin in clinical practice. Although it seems as a promising option for the prevention and therapy of thromboembolism, its safety and efficacy need to be determined definitely by further clinical trials.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Administration, Oral
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / complications*
  • Atrial Fibrillation / drug therapy
  • Azetidines / therapeutic use*
  • Benzylamines / therapeutic use*
  • Humans
  • Stroke / etiology*
  • Stroke / prevention & control*
  • Thromboembolism / etiology
  • Thromboembolism / prevention & control*
  • Warfarin / administration & dosage
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Azetidines
  • Benzylamines
  • ximelagatran
  • Warfarin